Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Viktor Boerlin"'
Autor:
Ian Lewis, Gisbert Weckbecker, Herbert A. Schmid, Steven W.J. Lamberts, Viktor Boerlin, Joost van der Hoek, Günter Bovermann, Lukas Oberer, Janos Pless, Nagarajan Chandramouli, Wilfried Bauer, Rainer Albert, Christian Bruns
Publikováno v:
CHIMIA, Vol 58, Iss 4 (2004)
A rational drug design approach involving transposition of functional groups from SRIF into a reduced size cyclohexapeptide template has led to the discovery of SOM230, a novel, stable cyclohexapeptide somatostatin mimic which exhibits unique high af
Externí odkaz:
https://doaj.org/article/d902474928ed4ac9b119a949dab0d176
Autor:
Tillmann Krahnke, Aart-Jan van der Lelij, Kwai W. Poon, Steven W. J. Lamberts, P. Uitterlinden, Viktor Boerlin, Joost van der Hoek, Wouter W. de Herder, Richard A Feelders, Ian Lewis, Leo J. Hofland
Publikováno v:
Clinical Endocrinology, 63, 176-184. Wiley-Blackwell Publishing Ltd
Summary Objective Recently, our first clinical study with the novel multiligand somatostatin (SRIF) analogue SOM230 in acromegalic patients showed that SOM230, due to its beneficial inhibitory effects on GH levels compared with octreotide (OCT), migh
Autor:
Tillmann Krahnke, Steven W. J. Lamberts, Kwai W. Poon, Joost van der Hoek, Leo J. Hofland, Ian Lewis, Wouter W. de Herder, Christian Bruns, Gisbert Weckbecker, Aart-Jan van der Lely, Richard A Feelders, Viktor Boerlin, P. Uitterlinden
Publikováno v:
Journal of Clinical Endocrinology and Metabolism, 89(2), 638-645. Endocrine Society
Treatment with the somatostatin receptor (sst) subtype 2 predominant analogs octreotide and lanreotide induces clinical and biochemical cure in approximately 65% of acromegalic patients. GH-secreting pituitary adenomas, which are not controlled, also
Autor:
Marco Salvatore, Diego Ferone, Annamaria Colao, Letizia Spinelli, Viktor Boerlin, Gaetano Lombardi, Paolo Marzullo, Alberto Cuocolo, Ioana Lancranjan, Domenico Bonaduce
Publikováno v:
Università degli Studi di Napoli Federico II
Cardiovascular disease is the most severe complication of acromegaly accounting for the increased mortality of these patients. Recently, the slow-release form of octreotide (OCT; Sandostatin LAR, OCT-LAR), for im injection every 28 days, was reported
Autor:
Lukas Oberer, Christian Bruns, Gisbert Weckbecker, Viktor Boerlin, Ian Lewis, Janos Pless, Rainer Albert, Nagarajan Chandramouli, Günter Bovermann, Steven W. J. Lamberts, Joost van der Hoek, Wilfried Bauer, Herbert A. Schmid
Publikováno v:
CHIMIA, Vol 58, Iss 4 (2004)
A rational drug design approach involving transposition of functional groups from SRIF into a reduced size cyclohexapeptide template has led to the discovery of SOM230, a novel, stable cyclohexapeptide somatostatin mimic which exhibits unique high af